RECRUITING

Growth Hormone Resistance of Beta-cells

Talk to us

Conditions

Gestational DiabetesObesityHealthy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes and type 2 diabetes.

Official Title

Growth Hormone Resistance of Beta-cells in Women With Gestational Diabetes Mellitus

Quick Facts

Study Start:2025-05-01
Study Completion:2030-09-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06571487

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Singleton, full term pregnancy within the past 5 years
  2. * Hemoglobin HbA1c ≤5.6% and fasting blood glucose \<100 mg/dl
  3. * Body mass index ≥30.0 kg/m2 and \<45.0 kg/m2, because the majority of women with GDM have overweight/obesity
  1. * Pregnant, planning to become pregnant during the study, or breastfeeding
  2. * Current diagnosis or history of type 1 or type 2 diabetes
  3. * Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
  4. * History of bariatric surgery
  5. * Known hypothyroidism or use of thyroid medications
  6. * History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
  7. * Current cancer or cancer that has been in remission less than 5 years
  8. * First degree relative with diabetes diagnosis
  9. * Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
  10. * Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
  11. * Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
  12. * Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

Contacts and Locations

Study Contact

Amanda Heider
CONTACT
573-884-6852
ahmc4@health.missouri.edu
Vasavi Shabrish, PhD
CONTACT
v.shabrish@missouri.edu

Principal Investigator

Bettina Mittendorfer, PhD
PRINCIPAL_INVESTIGATOR
University of Missouri-Columbia

Study Locations (Sites)

University of Missouri School of Medicine
Columbia, Missouri, 65212
United States

Collaborators and Investigators

Sponsor: University of Missouri-Columbia

  • Bettina Mittendorfer, PhD, PRINCIPAL_INVESTIGATOR, University of Missouri-Columbia

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-01
Study Completion Date2030-09-01

Study Record Updates

Study Start Date2025-05-01
Study Completion Date2030-09-01

Terms related to this study

Additional Relevant MeSH Terms

  • Gestational Diabetes
  • Obesity
  • Healthy